ASRA Provides Feedback on AHRQ Reports Regarding Acute Pain and Episodic MigraineSep 28, 2020
Today, ASRA submitted comments to the Agency for Healthcare Research and Quality (AHRQ) regarding its reports "Treatments for Acute Pain: A Systematic Review" and "Acute Treatments for Episodic Migraine."
"Treatments for Acute Pain: A Systematic Review" summarizes the AHRQ evaluation of the effectiveness and comparative effectiveness of opioid, nonopioid, pharmacologic, and nonpharmacologic therapy for treatment of acute pain.
ASRA made specific comments regarding 1) acute neck pain with radiculopathy, 2) renal colic, and 3) acute neuropathic pain in order to align those statements more with current available evidence and guidelines. View the letter here.
"Acute Treatments for Episodic Migraine" provides an evaluation of the effectiveness and comparative effectiveness of pharmacologic and non-pharmacologic therapies for the acute treatment of episodic migraine in adults.
ASRA provided feedback that some additional treatment options should be included in the report. These treatments are intranasal lidocaine, IV and oral magnesium, and diclofenec potassium and celecoxib oral solution. View the letter here.
Regulatory advocacy is a key component of ASRA's three-pronged mission to improve patient outcomes. Learn more about ASRA's advocacy work here.